Cargando…

Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients

SUMMARY: Outcomes for melanoma patients with stage III disease differ widely even within the same subcategory. Molecular signatures that more accurately predict prognosis are needed to stratify patients according to risk. Proteomic analyses were used to identify differentially abundant proteins in e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mactier, Swetlana, Kaufman, Kimberley L, Wang, Penghao, Crossett, Ben, Pupo, Gulietta M, Kohnke, Philippa L, Thompson, John F, Scolyer, Richard A, Yang, Jean Y, Mann, Graham J, Christopherson, Richard I
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285183/ https://www.ncbi.nlm.nih.gov/pubmed/24995518 http://dx.doi.org/10.1111/pcmr.12290

Ejemplares similares

Surface antigen profiles of leukocytes and melanoma cells in lymph node metastases are associated with survival in AJCC stage III melanoma patients
por: Kaufman, Kimberley L., et al.
Publicado: (2014)

Melanoma and the Unfolded Protein Response
por: Sykes, Erin K., et al.
Publicado: (2016)

The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia
por: Kaufman, Kimberley L., et al.
Publicado: (2015)

OTHR-08. PREDICTION OF RISK OF CENTRAL NERVOUS SYSTEM METASTASIS FOR AJCC 8(TH) EDITION STAGE III MELANOMA PATIENTS
por: Haydu, Lauren, et al.
Publicado: (2019)

Cladribine and Fludarabine Nucleoside Change the Levels of CD Antigens on B-Lymphoproliferative Disorders
por: Cassano, Carlos, et al.
Publicado: (2010)

Oncogenic B-RAF(V600E) signaling induces the T-box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion
por: Boyd, Suzanah C., et al.
Publicado: (2012)

Identifying High-Risk Tumors within AJCC Stage IB–III Melanomas Using a Seven-Marker Immunohistochemical Signature
por: Reschke, Robin, et al.
Publicado: (2021)

Identification of new prognostic biomarkers for Stage III metastatic melanoma patients
por: Kakavand, Hojabr, et al.
Publicado: (2013)

A Population-Based Comparison of the AJCC 7th and AJCC 8th Editions for Patients Diagnosed with Stage III Cutaneous Malignant Melanoma in Sweden
por: Isaksson, Karolin, et al.
Publicado: (2019)

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing
por: Pupo, Gulietta M., et al.
Publicado: (2017)

Use of S-100B to Evaluate Therapy Effects during Bevacizumab Induction Treatment in AJCC Stage III Melanoma
por: Kruijff, S., et al.
Publicado: (2011)

S‐100B as an extra selection tool for FDG PET/CT scanning in follow‐up of AJCC stage III melanoma patients
por: Deckers, Eric A., et al.
Publicado: (2019)

Impact of the 2009 (7th Edition) AJCC Melanoma Staging System in the Classification of Thin Cutaneous Melanomas
por: Chu, Vicki H., et al.
Publicado: (2013)

Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV)
por: Lotem, M, et al.
Publicado: (2002)

Comparison of seventh and eighth edition of AJCC staging system in melanomas at locoregional stage
por: Teterycz, Pawel, et al.
Publicado: (2019)

A randomised trial evaluating bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma: an update
por: Biswas, S, et al.
Publicado: (2008)

Dermoscopic characteristics of melanoma according to the criteria „ulceration“ and „mitotic rate“ of the AJCC 2009 staging system for melanoma
por: Deinlein, Teresa, et al.
Publicado: (2017)

Cross-Platform Omics Prediction procedure: a statistical machine learning framework for wider implementation of precision medicine
por: Wang, Kevin Y. X., et al.
Publicado: (2022)

Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis
por: Krisp, Christoph, et al.
Publicado: (2018)

AJCC cancer staging manual
Publicado: (1998)

IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma
por: Reijers, Irene L.M., et al.
Publicado: (2023)

Variation in the RAD51 gene and familial breast cancer
por: Lose, Felicity, et al.
Publicado: (2006)

Retinoblastoma Survival Following Primary Enucleation by AJCC Staging
por: Zhao, Junyang, et al.
Publicado: (2021)

Vitronectin and dermcidin serum levels predict the metastatic progression of AJCC I–II early‐stage melanoma
por: Ortega‐Martínez, Idoia, et al.
Publicado: (2016)

Posterior uveal melanoma incidence and survival by AJCC tumour size in a 70‐year nationwide cohort
por: Smidt‐Nielsen, Isabel, et al.
Publicado: (2021)

Concordance and Reproducibility of Melanoma Staging According to the 7th vs 8th Edition of the AJCC Cancer Staging Manual
por: Elmore, Joann G., et al.
Publicado: (2018)

Discriminatory Ability and Clinical Utility of the AJCC7 and AJCC8 Staging Systems for Breast Cancer in a Middle-Income Setting
por: Song, Chin-Vern, et al.
Publicado: (2023)

Survival analysis following resection of AJCC stage III gallbladder carcinoma based on different combinations of T and N stages
por: Hwang, Kyoung-Yeon, et al.
Publicado: (2015)

Better cancer specific survival in young small cell lung cancer patients especially with AJCC stage III
por: Wang, Haiyong, et al.
Publicado: (2017)

Primary oesophageal melanoma - a case report
por: Song, Eric J, et al.
Publicado: (2014)

AJCC 7th edition staging classification is more applicable than AJCC 8th edition staging classification for invasive IPMN
por: Fan, Zhiyao, et al.
Publicado: (2019)

Comparative study between two different staging systems (AJCC TNM VS BALLANTYNE’S) for mucosal melanomas of the Head & Neck
por: Luna-Ortiz, Kuauhyama, et al.
Publicado: (2016)

A population-based validation study of the 8th edition UICC/AJCC TNM staging system for cutaneous melanoma
por: Hynes, Matthew C., et al.
Publicado: (2022)

Prognostic stratification of patients with AJCC 2018 pN1 disease in stage III oral squamous cell carcinoma
por: Tsai, Ming-Hsien, et al.
Publicado: (2022)

A Review of Key Biological and Molecular Events Underpinning Transformation of Melanocytes to Primary and Metastatic Melanoma
por: Jackett, Louise A., et al.
Publicado: (2019)

Combined targeted therapy and immunotherapy in the treatment of advanced melanoma
por: Wilmott, James S., et al.
Publicado: (2012)

The IGCA staging system is more accurate than AJCC7 system in stratifying survival of patients with gastric cancer in stage III
por: Shu, Ping, et al.
Publicado: (2017)

Evaluation of the new AJCC staging system for resectable hepatocellular carcinoma
por: Cheng, Chih H, et al.
Publicado: (2011)

Comprehensive proteome profiling of glioblastoma-derived extracellular vesicles identifies markers for more aggressive disease
por: Mallawaaratchy, Duthika M., et al.
Publicado: (2016)

Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses
por: Yang, Yaewon, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_cdra2rrm31to20ge8re9o9s9js